Opthea has discontinued development of sozinibercept in wet age-related macular degeneration, according to a press release.

An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

(RTTNews) - Opthea Limited (OPT, OPT.AX) announced its decision to discontinue the development of sozinibercept for wet age-related macular degeneration or wet AMD. This follows the negative ...

Opthea said it agreed with the investors in its development funding agreement to end development of sozinibercept in wet AMD, and that the move wouldn't constitute a termination event under the ...

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea and DFA Investors agreed to terminate both COAST and ShORe trials ...

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...

Leerink downgraded Opthea (OPT) to Market Perform from Outperform with a price target of $1, down from $12. The firm cites the company ...

Opthia could owe its investors more than $1bn following the results of its Phase III Combination OPT-302 with Aflibercept Study (COAST) trial (NCT04757636), which evaluated its sozinibercept ...